Biotech Industry Faces Revival as FDA Issues Loom in 2026
Biotech investors can expect a significant shift in the market landscape in 2026, according to industry expert Bruce Booth, a partner at Atlas Venture. His insights indicate that after two…
Durvalumab and Chemoradiotherapy Show No Survival Benefit in NSCLC
New research presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer has revealed that the combination of durvalumab (Imfinzi) and chemoradiotherapy does…